Dermatology Reports (Oct 2024)

Calcipotriol as a daylight photodynamic therapy enhancer: a case-control study

  • Benedetta Sonego,
  • Enrico Zelin,
  • Serena Bonin,
  • Tommaso Pozzebon,
  • Giulia Bazzacco,
  • Andrea Corio,
  • Marina Agozzino,
  • Dante Raffaele Caro Caposieno,
  • Iris Zalaudek,
  • Nicola di Meo

DOI
https://doi.org/10.4081/dr.2024.10077

Abstract

Read online

Actinic keratoses (AKs) are common skin lesions found on sun-exposed areas and are considered potential precursors to squamous cell carcinomas (SCCs). This observational case-control study evaluates the efficacy of combining traditional daylight photodynamic therapy (DL-PDT) with pre-treatment using 0.005% calcipotriol (CAL) ointment. Twenty immunocompetent male patients with grade I-II AKs on the scalp and/or face were randomized into two groups: the case group received a 14-day pretreatment with CAL ointment before DL-PDT, while the control group used a moisturizing cream. Both groups underwent a series of three DL-PDT sessions. The study utilized the Actinic Keratosis Area Severity Index (AKASI) scoring system to measure the actinic damage at baseline, 3 months, and 6 months post-treatment. Results showed a significant reduction in AKASI scores in the CAL group compared to controls, indicating that CAL pretreatment enhances the efficacy of DL-PDT. This combination treatment was well tolerated, with minimal discomfort reported. The findings suggest that incorporating CAL into the treatment regimen can improve the clearance of AKs and potentially prevent their progression to SCCs.

Keywords